{"id":56224,"date":"2023-04-26T10:03:16","date_gmt":"2023-04-26T08:03:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/"},"modified":"2023-04-26T10:03:16","modified_gmt":"2023-04-26T08:03:16","slug":"diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/","title":{"rendered":"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives"},"content":{"rendered":"
\n

\nTA\u2019s investment supports Diatech\u2019s expansion of precision medicine diagnostics to the global market<\/i><\/p>\n

JESI, MARCHE, Italy–(BUSINESS WIRE)–Diatech Pharmacogenetics (\u201cDiatech\u201d or \u201cthe Company\u201d), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (\u201cTA\u201d), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in the Company. As part of the transaction, minority investor Alto Partners will fully exit its stake in the business. Diatech\u2019s founder and management team will retain majority ownership of the Company, partnering closely with TA.<\/p>\n

<\/a><\/p>\n

\nDiatech produces and distributes genomics testing solutions to identify gene mutations and genetic differences that are targets of personalized cancers therapies and that influence patient responses to specific treatments. With these tests, Diatech aims to increase the effectiveness of cancer medicine through personalized diagnosis and treatments.<\/p>\n

\n\u201cWe are excited to welcome TA on this journey with us amid a period of great advancement in precision medicine,\u201d said Fabio Biondi, Founder and President of Diatech. \u201cTA offers extensive operational experience and a wide global network that will be critical as we strive to accelerate our international growth and product innovation. We also thank Alto Partners for helping us reach this milestone in our growth journey.\u201d<\/p>\n

\nFounded in 1996, Diatech has demonstrated strong growth in recent years and today is among the first players into the EU market for oncology diagnostics. TA\u2019s investment will support Diatech\u2019s continued development of market-leading diagnostic solutions and reagents in the pharmacogenetics sectors, as well as its global growth initiatives, furthering the Company\u2019s position as a leader in the rapidly expanding molecular diagnostics market.<\/p>\n

\n\u201cAs technology improves and there is a greater shift toward precision medicine, continued advancements in the genomic testing landscape are essential,\u201d said Oliva Alberti, CEO of Diatech. \u201cThis strategic partnership with TA will allow us to widen the reach of our existing products and services, while also making a meaningful expansion into international markets.\u201d<\/p>\n

\n\u201cDiatech\u2019s comprehensive, market-leading product portfolio highlights the Company\u2019s commitment to a rigorous and differentiated R&D process that consistently drives value creation,\u201d said Lovisa Lander, Director at TA. \u201cWe look forward to partnering with Fabio, Oliva, and the entire management team to support Diatech\u2019s international and domestic growth journey.\u201d<\/p>\n

\n\u201cThe Company\u2019s proven track record and leading position in its market mean it is well positioned to capitalize on organic and inorganic growth opportunities, expanding its addressable market and extensive product portfolio,\u201d said Birker Bahnsen, Managing Director at TA and head of the firm\u2019s Europe Healthcare Group. \u201cWe are thrilled to support Diatech on its next phase of growth.\u201d<\/p>\n

\n\u201cSince our investment in 2021, Diatech has achieved strong organic growth, expanded into new global markets and broadened its product portfolio,\u201d said Enrico Ricotta, Senior Partner at Alto Partners. \u201cIt has been a privilege to work with the entire Diatech team and we wish them the best as they build on their continued success in partnership with TA.\u201d<\/p>\n

\nThe transaction is expected to close in the second quarter of 2023 pending customary regulatory approval.<\/p>\n

\nFinancial terms of the transaction were not disclosed.<\/p>\n

\nAbout Diatech Pharmacogenetics<\/b><\/p>\n

\nDiatech Pharmacogenetics is a leading Italian company in the development, production and commercialization of molecular diagnostic tools for precision oncology medicine. Founded in 1996, the company aims to simplify complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acid extraction and molecular analysis to final reporting. Diatech has shown strong growth in recent years and today is among the first players in the EU market for the oncology diagnostics market. To learn more, visit www.diatechpharmacogenetics.com<\/a><\/p>\n

\nAbout TA<\/b><\/p>\n

\nTA Associates (\u201cTA\u201d) is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries \u2013 technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $48.6 billion in capital to date and has more than 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit www.ta.com<\/a>.<\/p>\n

\nAbout Alto Partners<\/b><\/p>\n

\nAlto Partners SGR, an independent company, is controlled by its expert multidisciplinary team to promote and manage private equity funds investing in small-to-medium-sized Italian companies. Alto Partners is a proven experienced, professional and reliable partner in supporting the medium-to-long-term development of our portfolio companies. Together, Alto Partners SGR works alongside industrial families and managers to oversee generational transitions and growth programs. To learn more, visit www.altopartners.it<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMaggie Benoit<\/i>
Communications Manager, TA<\/i>
mbenoit@ta.com<\/a><\/i><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TA\u2019s investment supports Diatech\u2019s expansion of precision medicine diagnostics to the global market JESI, MARCHE, Italy–(BUSINESS WIRE)–Diatech Pharmacogenetics (\u201cDiatech\u201d or \u201cthe Company\u201d), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (\u201cTA\u201d), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56224","6":"format-standard","7":"category-industry"},"yoast_head":"\nDiatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TA\u2019s investment supports Diatech\u2019s expansion of precision medicine diagnostics to the global market JESI, MARCHE, Italy–(BUSINESS WIRE)–Diatech Pharmacogenetics (\u201cDiatech\u201d or \u201cthe Company\u201d), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (\u201cTA\u201d), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T08:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230426005178\/en\/1774287\/21\/Diatech_LinkedIn.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives\",\"datePublished\":\"2023-04-26T08:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/\"},\"wordCount\":788,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005178\\\/en\\\/1774287\\\/21\\\/Diatech_LinkedIn.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/\",\"name\":\"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005178\\\/en\\\/1774287\\\/21\\\/Diatech_LinkedIn.jpg\",\"datePublished\":\"2023-04-26T08:03:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005178\\\/en\\\/1774287\\\/21\\\/Diatech_LinkedIn.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005178\\\/en\\\/1774287\\\/21\\\/Diatech_LinkedIn.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/","og_locale":"en_US","og_type":"article","og_title":"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives - Pharma Trend","og_description":"TA\u2019s investment supports Diatech\u2019s expansion of precision medicine diagnostics to the global market JESI, MARCHE, Italy–(BUSINESS WIRE)–Diatech Pharmacogenetics (\u201cDiatech\u201d or \u201cthe Company\u201d), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (\u201cTA\u201d), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-26T08:03:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230426005178\/en\/1774287\/21\/Diatech_LinkedIn.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives","datePublished":"2023-04-26T08:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/"},"wordCount":788,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005178\/en\/1774287\/21\/Diatech_LinkedIn.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/","url":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/","name":"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005178\/en\/1774287\/21\/Diatech_LinkedIn.jpg","datePublished":"2023-04-26T08:03:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230426005178\/en\/1774287\/21\/Diatech_LinkedIn.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230426005178\/en\/1774287\/21\/Diatech_LinkedIn.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/diatech-pharmacogenetics-announces-investment-from-ta-to-fuel-strategic-growth-initiatives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56224"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56224\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}